Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC.
- DOI
- 10.1016/j.jtocrr.2025.100900
- Published
- 2025 Oct
- Container
- JTO clinical and research reports
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtocrr.2025.100900,
title = {Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC.},
author = {Lim SM and Ortega Granados AL and Pinto GDJ and Fuentes CS and Lo Russo G and Schenker M and Ahn JS and de Marinis F and Locke K Jr and Szijgyarto Z and Buss E and Stjepanovic N and Diaz-Padilla I and Peters S},
year = {2025},
journal = {JTO clinical and research reports},
doi = {10.1016/j.jtocrr.2025.100900},
url = {https://doi.org/10.1016/j.jtocrr.2025.100900}
}RIS
TY - JOUR TI - Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC. AU - Lim SM AU - Ortega Granados AL AU - Pinto GDJ AU - Fuentes CS AU - Lo Russo G AU - Schenker M AU - Ahn JS AU - de Marinis F AU - Locke K Jr AU - Szijgyarto Z AU - Buss E AU - Stjepanovic N AU - Diaz-Padilla I AU - Peters S PY - 2025 JO - JTO clinical and research reports DO - 10.1016/j.jtocrr.2025.100900 UR - https://doi.org/10.1016/j.jtocrr.2025.100900 ER -
APA
SM, L., AL, O. G., GDJ, P., CS, F., G, L. R., M, S., JS, A., F, D. M., Jr, L. K., Z, S., E, B., N, S., I, D., & S, P. (2025). Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC.. JTO clinical and research reports. https://doi.org/10.1016/j.jtocrr.2025.100900
Source records
- pubmed · retrieved 2026-09-26T09:00:53.615Z